|Articles|September 25, 2014
- Gynecologic Cancers (Issue 1)
- Volume 1
- Issue 1
Cediranib Versus Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer
Author(s)Jyoti D. Patel, MD
Jyoti D. Patel, MD, discusses a phase II trial that looked at olaparib in combination with cediranib versus olaparib alone in recurrent platinum-sensitive ovarian cancer.
Jyoti D. Patel, MD, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses a phase II trial that looked at olaparib in combination with cediranib versus olaparib alone in recurrent platinum-sensitive ovarian cancer. This trial was presented by Dr. Joyce Liu at the 2014 ASCO Annual Meeting.
Learn more about potentially promising treatments for ovarian cancer > >
Articles in this issue
about 11 years ago
The Role of Molecular Testing in Gynecologic Cancersabout 11 years ago
Trabectedin as a Treatment Option for Patients with Ovarian Cancerabout 11 years ago
Dream Team Aims To Change the Face of Ovarian Cancer Researchabout 11 years ago
On The Horizon for Ovarian Cancer: Potentially Promising TreatmentsRelated Content
Advertisement
